Brief: Knight Therapeutics Announces Regulatory Supplemental Submission Of Minjuvi® (Tafasitamab) For Follicular Lymphoma In Argentina And Mexico
17/03/2026 11:42
March 17 (Reuters) - Knight Therapeutics Inc GUD.TO: KNIGHT THERAPEUTICS ANNOUNCES REGULATORY SUPPLEMENTAL SUBMISSION OF MINJUVI® (TAFASITAMAB) FOR FOLLICULAR LYMPHOMA IN ARGENTINA AND MEXICO Source text: ID:nGNX2FX71k Further company coverage: GUD.TO ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Knight Therapeutics
See all newsBrief: Knight Therapeutics Announces Regulatory Approval Of Niktimvo In Brazil
Brief: Knight Therapeutics - Launches Tavalisse In Brazil For Chronic Immune Thrombocytopenia
Brief: Knight Therapeutics Enters Into Exclusive Distribution Agreement With Kyowa Kirin International For Poteligeo® (Mogamulizumab)
Brief: Knight Therapeutics Announces Regulatory Approval Of Tavalisse® In Colombia
Brief: Knight Therapeutics Announces Supplemental Regulatory Submission For Minjuvi In Brazil